article thumbnail

Liposome: A Novel Drug Delivery System

Roots Analysis

The hydrophobic portion contains two fatty acid chains with 10-24 carbon atoms, while the hydrophilic part primarily consists of phosphoric acid linked to a water-soluble molecule. Therapeutic Applications of Liposomes in Drug Delivery In comparison to existing formulations, liposomes offer greater therapeutic efficacy and safety.

article thumbnail

STAT+: Pharmalittle: Moderna must face patent claims over its Covid-19 vaccine; Pfizer and BioNTech testing combo Covid and flu shot

STAT News

… A Delaware federal court refused to throw out patent infringement claims brought by Arbutus Biopharma and Genevant Sciences against Moderna over its sale of Covid-19 vaccine doses to the U.S.  Genevant and Arbutus sued Moderna in February, seeking royalties from Moderna’s sale of its Covid-19 vaccine.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

mRNA Therapeutics and mRNA Vaccines Industry: Current Scenario and Future Trends

Roots Analysis

In the last few years, researchers have become interested in using in vitro transcribed (IVT) mRNA as a drug delivery agent. It is worth noting that several companies have begun to develop mRNA-based cancer immunotherapies and vaccines for infectious diseases.

article thumbnail

mRNA Synthesis: ManufacturingProcess of Modern Revolutionary Molecule

Roots Analysis

Presently, more than 195 mRNA therapeutics / mRNA vaccines are under development or commercialized for the treatment of a variety of indications. The production of such drug products requires skilled labor, stringent manufacturing protocols and specialized expertise.

article thumbnail

MYELOID CELL TARGETING THERAPEUTICS: BUDDING THERAPY AGAINST CANCER

Roots Analysis

Myeloid cells represent a group of cells containing granulocytes, monocytes, macrophages, mast cells and dendritic cells, which play a key role in innate immunity. These cells are found in abundance in the tumor microenvironment and inflamed areas. Our Social Media Platform. Web: [link]. LinkedIn: [link]. Twitter: [link]. Medium: [link].

article thumbnail

Darzalex Faspro (daratumumab and hyaluronidase-fihj) Becomes the First FDA-Approved Treatment for Patients with Newly Diagnosed Light Chain (AL) Amyloidosis

The Pharma Data

Darzalex Faspro® is co-formulated with recombinant human hyaluronidase PH20 (rHuPH20), Halozyme’s ENHANZE® drug delivery technology. Darzalex Faspro® is the only CD38-directed antibody approved to be given subcutaneously to treat patients with multiple myeloma and now AL amyloidosis. Learn more at www.janssen.com.